Search

Your search keyword '"Cannavo, S."' showing total 217 results
Start Over Author "Cannavo, S."
217 results on '"Cannavo, S."'

1. Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study

Author

Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, K., Pimpinelli, N., Parodi, A., Fargnoli, M. C., Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, M., Bianchi, L., and Offidani, A.

Published
2022
Full Text
View/download PDF

2. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study

Author

Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, K., Pimpinelli, N., Parodi, A., Fargnoli, M. C., Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, M., Bianchi, L., and Offidani, A.

Published
2022
Full Text
View/download PDF

3. Venous thromboembolism in Cushing syndrome:results from an EuRRECa and Endo-ERN survey

Author

Cherenko, M., Appelman-Dijkstra, N. M., Zurita, A. L.Priego, Biermasz, N. R., Dekkers, O. M., Klok, F. A., Reisch, N., Aulinas, A., Biagetti, B., Cannavo, S., Canu, L., Detomas, M., Devuyst, F., Falhammar, H., Feelders, R. A., Ferrau, F., Gatto, F., Grasselli, C., van Houten, P., Hoybye, C., Isidori, A. M., Kyrilli, A., Loli, P., Maiter, D., Nowak, E., Pivonello, R., Ragnarsson, O., Steenaard, R. V., Unger, N., van de Ven, A., Webb, S. M., Yeste, D., Ahmed, S. F., Pereira, A. M., Cherenko, M., Appelman-Dijkstra, N. M., Zurita, A. L.Priego, Biermasz, N. R., Dekkers, O. M., Klok, F. A., Reisch, N., Aulinas, A., Biagetti, B., Cannavo, S., Canu, L., Detomas, M., Devuyst, F., Falhammar, H., Feelders, R. A., Ferrau, F., Gatto, F., Grasselli, C., van Houten, P., Hoybye, C., Isidori, A. M., Kyrilli, A., Loli, P., Maiter, D., Nowak, E., Pivonello, R., Ragnarsson, O., Steenaard, R. V., Unger, N., van de Ven, A., Webb, S. M., Yeste, D., Ahmed, S. F., and Pereira, A. M.

Abstract

Background: Patients with Cushing syndrome (CS) are at increased risk of venous thromboembolism (VTE). Objective: The aim was to evaluate the current management of new cases of CS with a focus on VTE and thromboprophylaxis. Design and methods: A survey was conducted within those that report in the electronic reporting tool (e-REC) of the European Registries for Rare Endocrine Conditions (EuRRECa) and the involved main thematic groups (MTG’s) of the European Reference Networks for Rare Endocrine Disorders (Endo-ERN) on new patients with CS from January 2021 to July 2022. Results: Of 222 patients (mean age 44 years, 165 females), 141 patients had Cushing disease (64%), 69 adrenal CS (31%), and 12 patients with ectopic CS (5.4%). The mean follow-up period post-CS diagnosis was 15 months (range 3–30). Cortisol-lowering medications were initiated in 38% of patients. One hundred fifty-four patients (69%) received thromboprophylaxis (including patients on chronic anticoagulant treatment), of which low-molecular-weight heparins were used in 96% of cases. VTE was reported in six patients (2.7%), of which one was fatal: two long before CS diagnosis, two between diagnosis and surgery, and two postoperatively. Three patients were using thromboprophylaxis at time of the VTE diagnosis. The incidence rate of VTE in patients after Cushing syndrome diagnosis in our study cohort was 14.6 (95% CI 5.5; 38.6) per 1000 person-years. Conclusion: Thirty percent of patients with CS did not receive preoperative thromboprophylaxis during their active disease stage, and half of the VTE cases even occurred during this stage despite thromboprophylaxis. Prospective trials to establish the optimal thromboprophylaxis strategy in CS patients are highly needed. Significance statement The incidence rate of venous thromboembolism in our study cohort was 14.6 (95% CI 5.5; 38.6) per 1000 person-years. N

Published
2024

4. Gender differences in adult atopic dermatitis and clinical implication: Results from a nationwide multicentre study.

Author

Marani, A., Bianchelli, T., Gesuita, R., Faragalli, A., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, K., Pimpinelli, N., Parodi, A., Fargnoli, M. C., Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., and Argenziano, G.

Subjects
ATOPIC dermatitis, ITCHING, AGE differences, WAIST-hip ratio, DISEASE duration, ADULTS
Abstract

Background: Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults. However, limited research has been conducted on gender differences in AD. Objectives: This study aimed to assess gender differences in adult AD patients, focusing on demographic and clinical features, comorbidities and treatment approaches. Methods: In this multicentre, observational, cross‐sectional study, we enrolled 686 adult patients with AD (357 males and 329 females). For each patient, we collected demographic data (age and sex), anthropometric measurements (weight, height, hip circumference, waist circumference and waist‐to‐hip ratio), clinical information (onset age, disease duration, severity, itching intensity, impact on quality of life) and noted comorbidities (metabolic, atopic and other). We recorded past and current topical and systemic treatments. We analysed all collected data using statistical techniques appropriate for both quantitative and qualitative variables. Multiple correspondence analysis (MCA) was employed to evaluate the relationships among all clinical characteristics of the patients. Results: We found no differences in age at onset, disease duration, severity and quality of life impact between males and females. Males exhibited higher rates of hypertriglyceridaemia and hypertension. No significant gender differences were observed in atopic or other comorbidities. Treatment approaches were overlapping, except for greater methotrexate use in males. MCA revealed distinct patterns based on gender, disease severity, age of onset, treatment and quality of life. Adult males with AD had severe disease, extensive treatments and poorer quality of life, while adult females had milder disease, fewer treatments and moderate quality of life impact. Conclusions: Our study reveals that gender differences in adult AD patients are largely due to inherent population variations rather than disease‐related disparities. However, it highlights potential undertreatment of females with moderate AD and quality of life impact, emphasizing the need for equitable AD treatment. JAK inhibitors may offer a solution for gender‐based therapeutic parity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life

Author

Cangiano, B, Giusti, E, Premoli, C, Soranna, D, Vitale, G, Grottoli, S, Cambria, V, Mantovani, G, Mungari, R, Maffei, P, Dassie, F, Giampietro, A, Chiloiro, S, Tanda, M, Ippolito, S, Cannavo, S, Ragonese, M, Zambon, A, Persani, L, Fatti, L, Scacchi, M, Cavagnini, F, Ferone, D, Corbetta, S, Bartalena, L, Peccoz, P, Arosio, M, Lania, A, Colao, A, Pivonello, R, Uberti, E, Ghigo, E, Giustina, A, Martino, E, Pontecorvi, A, Sicolo, N, Trimarchi, F, Cangiano B., Giusti E., Premoli C., Soranna D., Vitale G., Grottoli S., Cambria V., Mantovani G., Mungari R., Maffei P., Dassie F., Giampietro A., Chiloiro S., Tanda M. L., Ippolito S., Cannavo S., Ragonese M., Zambon A., Persani L., Fatti L. M., Scacchi M., Cavagnini F., Ferone D., Corbetta S., Bartalena L., Peccoz P. B., Arosio M., Lania A., Colao A., Pivonello R., Uberti E. D., Ghigo E., Giustina A., Martino E., Pontecorvi A., Sicolo N., Trimarchi F., Cangiano, B, Giusti, E, Premoli, C, Soranna, D, Vitale, G, Grottoli, S, Cambria, V, Mantovani, G, Mungari, R, Maffei, P, Dassie, F, Giampietro, A, Chiloiro, S, Tanda, M, Ippolito, S, Cannavo, S, Ragonese, M, Zambon, A, Persani, L, Fatti, L, Scacchi, M, Cavagnini, F, Ferone, D, Corbetta, S, Bartalena, L, Peccoz, P, Arosio, M, Lania, A, Colao, A, Pivonello, R, Uberti, E, Ghigo, E, Giustina, A, Martino, E, Pontecorvi, A, Sicolo, N, Trimarchi, F, Cangiano B., Giusti E., Premoli C., Soranna D., Vitale G., Grottoli S., Cambria V., Mantovani G., Mungari R., Maffei P., Dassie F., Giampietro A., Chiloiro S., Tanda M. L., Ippolito S., Cannavo S., Ragonese M., Zambon A., Persani L., Fatti L. M., Scacchi M., Cavagnini F., Ferone D., Corbetta S., Bartalena L., Peccoz P. B., Arosio M., Lania A., Colao A., Pivonello R., Uberti E. D., Ghigo E., Giustina A., Martino E., Pontecorvi A., Sicolo N., and Trimarchi F.

Abstract

Purpose: Current treatment of acromegaly restores a normal life expectancy in most cases. So, the study of persistent complications affecting patients’ quality of life (QoL) is of paramount importance, especially motor disability and depression. In a large cohort of acromegalic patients we aimed at establishing the prevalence of depression, to look for clinical and sociodemographic factors associated with it, and to investigate the respective roles (and interactions) of depression and arthropathy in influencing QoL. Methods: One hundred and seventy-one acromegalic patients (95 women and 76 men, aged 20–85 years) among those recruited in a cross-sectional Italian multicentric study were investigated. Each patient filled in three validated questionnaires: AcroQoL, WOMAC (measuring articular pain, stiffness and functionality), and AIMS (evaluating articular symptoms and depression). Results: A very high (up to 28%) depression rate was detected in acromegalic subjects. Two patients showing pathological AIMS depression scores, committed suicide during the three years observational period. In our population poor psychological status was significantly associated with female sex. Furthermore, a significant strong correlation was found between AIMS depression score and WOMAC score. Both depression and arthropathy-related motor disability turned out to independently contribute with similar strength to the impairment of QoL. Conclusions: We report a high prevalence of depression in acromegaly, which is associated with female sex and arthropathy. Both depression and arthropathy strongly and independently contribute to the impaired QoL of patients. Our study shows that assessment and monitoring of psychological status is mandatory in acromegaly, also suggesting an inexpensive tool for this assessment.

Published
2022

9. COVID 19-associated chilblain-like acral lesions among children and adolescents: an Italian retrospective, multicenter study

Author

Romita, P., Maronese, C. A., de Marco, A., Balestri, R., Belloni Fortina, A., Brazzelli, V., Colonn, C., Di Lernia, V., El Hachem, May, Fabbrocini, G., Foti, C., Frasin, L. A., Guarneri, C., Guerriero, Cristina, Guida, S., Locatelli, A., Neri, Ilaria, Occella, C., Offidani, A., Oranges, T., Pellacani, G., Stinco, G., Stingeni, L., Barbagallo, T., Campanati, A., Cannavo, S. P., Caroppo, F., Cavalli, R., Costantini, Alessio, Cucchia, R., Diociaiuti, Andrea, Filippeschi, C., Francomano, M., Giancristoforo, S., Giuffrida, R., Martina, E., Monzani, N. A., Nappa, P., Pastorino, C., Patrizi, A., Peccerillo, F., Peris, Ketty, Recalcati, S., Rizzoli, L., Simonetti, O., Vastarella, M., Virdi, A., Marzano, A. V., Bonamonte, D., El Hachem M., Guerriero C., Neri I., Costantini A., Diociaiuti A., Peris K. (ORCID:0000-0002-5237-0463), Romita, P., Maronese, C. A., de Marco, A., Balestri, R., Belloni Fortina, A., Brazzelli, V., Colonn, C., Di Lernia, V., El Hachem, May, Fabbrocini, G., Foti, C., Frasin, L. A., Guarneri, C., Guerriero, Cristina, Guida, S., Locatelli, A., Neri, Ilaria, Occella, C., Offidani, A., Oranges, T., Pellacani, G., Stinco, G., Stingeni, L., Barbagallo, T., Campanati, A., Cannavo, S. P., Caroppo, F., Cavalli, R., Costantini, Alessio, Cucchia, R., Diociaiuti, Andrea, Filippeschi, C., Francomano, M., Giancristoforo, S., Giuffrida, R., Martina, E., Monzani, N. A., Nappa, P., Pastorino, C., Patrizi, A., Peccerillo, F., Peris, Ketty, Recalcati, S., Rizzoli, L., Simonetti, O., Vastarella, M., Virdi, A., Marzano, A. V., Bonamonte, D., El Hachem M., Guerriero C., Neri I., Costantini A., Diociaiuti A., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

BACKGROUND: Since the COVID-19 pandemic started, great interest has been given to this disease, especially to its possible clinical presentations. Besides classical respiratory symptoms, dermatological manifestations occur quite often among infected and non-infected patients, particularly in children. A prominent IFN-I response, that is generally higher in children compared to adults, may not only cause chilblain lesions, but it could also prevent infection and viral replication, thus justifying the negative swab results, as well as the absence of relevant systemic symptoms in positive cases. Indeed, reports have emerged describing chilblain-like acral lesions in children and adolescents with either proven or suspected infection. METHODS: Patients aged from 1 to 18 years old were enrolled in this study from 23 Italian dermatological units and were observed for an overall period of 6 months. Clinical pictures were collected along with data on the location and duration of skin lesions, their association with concomitant local and systemic symptoms, presence of nail and/or mucosal involvement, as well as histological, laboratory and imaging findings. RESULTS: One hundred thirty-seven patients were included, of whom 56.9% were females. Mean age was 11.97±3.66 years. The most commonly affected sites were the feet (77 patients, 56.2%). Lesions (48.5%) featured cyanosis, chilblains, blisters, ecchymosis, bullae, erythema, edema, and papules. Concomitant skin manifestations included maculo-papular rashes (30%), unspecified rashes (25%), vesicular rashes (20%), erythema multiforme (10%), urticaria (10%) and erythema with desquamation (5%). Forty-one patients (29.9%) reported pruritus as the main symptom associated with chilblains, and 56 out of 137 patients also reported systemic symptoms such as respiratory symptoms (33.9%), fever (28%), intestinal (27%), headache (5.5%), asthenia (3.5%), and joint pain (2%). Associated comorbid conditions were observed in 9 patients presen

Published
2023

10. Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement

Author

Cannavo, S., Cappa, M., Ferone, D., Isidori, A. M., Loche, S., Salerno, M., Maghnie, M., Aimaretti, G., Ambrosio, M. R., Bellone, S., Caruso, M., Castello, R., Ceccato, F., Cerbone, T., Cherubini, V., de Carlo, E., De Sanctis, L., della Casa, S., Di Somma, C., Faienza, M. F., Gasco, V., Gaudino, R., Giacomozzi, C., Giavoli, C., Guazzarotti, L., Klain, A., Lania, A., Leonardi, D., Longhi, S., Lughetti, L., Maggio, M. C., Wasniewska, G. M., Mameli, C., Mauro, C., Giudice, E. M. D., Palermo, M. C. A., Parpagnoli, M., Persani, L., Pilotta, A., Pozzobon, G., Rochira, V., Rota, F., Sacco, M., Scarcella, S., Scavuzzo, F., Sinisi, A. A., Street, M. E., Tornese, G., Cannavò, S., Cappa, M., Ferone, D., Isidori, A. M., Loche, S., Salerno, M., Maghnie, M., Tornese, G., Cannavò, S, Cappa, M, Ferone, D, Isidori, A M, Loche, S, Salerno, M, Maghnie, M, and Maggio, Maria Cristina

Subjects
growth hormone deficiency, Settore MED/38 - Pediatria Generale E Specialistica, Endocrinology, age of transition, consensus, Italian Delphi consensus statement, Endocrinology, Diabetes and Metabolism, adolescent, growth hormone, transition, Transition age
Abstract

Growth hormone deficiency (GHD) describes the impairment of growth hormone (GH) secretion by the pituitary somatotroph cells. GHD may be congenital, with causes, including genetic alterations and structural brain malformations, or acquired, including midline tumours, cranial irradiation, traumatic brain injury, central nervous system infections and inflammatory conditions. GHD in children is characterised by short stature, delayed bone maturation and abnormalities in substrate metabolism, body composition, physical and psychosocial functioning, all of which improve with recombinant human GH (rhGH) therapy. The diagnosis of GHD is based on clinical signs and symptoms, biochemistry and imaging. Although GH stimulation tests are considered the mainstay of diagnostic investigations, the results must be interpreted with caution owing to the variability in cut-off values and reproducibility. Transition refers to the physical and psychosocial changes in adolescent patients during the mid-teens to late teens (usually 15–18 years of age) until about 6–7 years after achievement of adult height. During the transition age, only a small residual capacity of longitudinal growth is left, but body maturity is not yet complete. Discontinuation of rhGH treatment at the end of longitudinal growth in adolescents with permanent GHD is associated with decreased muscle strength and mass, increased body fat (mainly in the abdomen), the arrest or reversal of muscle mass and bone mass density (BMD) gain and lipid profile deterioration. For these reasons, patients whose GHD persists during the transition age need to continue rhGH treatment to obtain full somatic maturation and normalisation of body composition, BMD, quality of life (QoL) and lipid metabolism. There is some evidence that rhGH treatment during transition may result in improved growth and bone health, as well as a better prognosis for metabolic and cardiovascular risks in the long term. Since these patients need to continue treatment to complete their body development, a multidisciplinary approach is required to ensure continuity of care during the transfer from paediatric to adult endocrinology services. Guidelines for the diagnosis and treatment of young adults with GHD have been published by the American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE), Endocrine Society, European Society of Paediatric Endocrinology (ESPE), Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society and Endocrine Society of Australia. However, clinical practice lacks uniformity in terms of diagnosis and treatment of transition-age patients, the impact of GH replacement during transition has not been adequately assessed in randomised clinical trials (RCTs), validated questionnaires to assess QoL in patients on rhGH treatment in the transition period are not available and there is still uncertainty about the multidisciplinary approach during transition [8]. Hence, a structured transition protocol is essential to establish the best practice for transitioning adolescents with GHD to adult care. A study in Italy in 2015 identified a low level of awareness of these issues in clinical practice and real-world gaps in the management of GHD patients during transition. To address these gaps and assist endocrinologists (adult and paediatric) in the diagnosis and treatment of GHD in transition-age patients, a Delphi consensus process was undertaken to develop clinically relevant recommendations. The current consensus statements address the diagnosis of GHD, benefits of treatment, monitoring and management of transition-age patients with GHD, along with treatment adherence and safety concerns.

Published
2023

11. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Author

Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., and Peris, K.

Abstract

Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen ‘cytokine storm’ of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

Published
2021

13. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author

Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., Zangrilli A., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., and Zangrilli A.

Published
2020

14. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w)

Author

Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, Anna Maria, Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Borghi A., Gori N., Gallo R., Tonini G., Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, Anna Maria, Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Borghi A., Gori N., Gallo R., and Tonini G.

Abstract

In this article the author group details were incorrectly displayed with Collaborators included in the main author group. M. Talamonti (Dermatology Unit, Policlinico Tor Vergata Rome, University of Rome Tor Vergata, Rome, Italy). The original article has been corrected.

Published
2022

16. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE)

Author

Caprio, M., Infante, M., Moriconi, E., Armani, A., Fabbri, A., Mantovani, G., Mariani, S., Lubrano, C., Poggiogalle, E., Migliaccio, S., Donini, L. M., Basciani, S., Cignarelli, A., Conte, E., Ceccarini, G., Bogazzi, F., Cimino, L., Condorelli, R. A., La Vignera, S., Calogero, A. E., Gambineri, A., Vignozzi, L., Prodam, F., Aimaretti, G., Linsalata, G., Buralli, S., Monzani, F., Aversa, A., Vettor, R., Santini, F., Vitti, P., Gnessi, L., Pagotto, U., Giorgino, F., Colao, A., Lenzi, A., Beccuti, G., Biondi, B., Cannavo, S., Chiodini, I., De Feudis, G., Di Francesco, S., Di Gregorio, A., Fallo, F., Foresta, C., Giacchetti, G., Granata, R., Isidori, A. M., Magni, P., Maiellaro, P., Caprino, M. P., Pivonello, R., Pofi, R., Pontecorvi, A., Simeoli, C., Caprio M., Infante M., Moriconi E., Armani A., Fabbri A., Mantovani G., Mariani S., Lubrano C., Poggiogalle E., Migliaccio S., Donini L.M., Basciani S., Cignarelli A., Conte E., Ceccarini G., Bogazzi F., Cimino L., Condorelli R.A., La Vignera S., Calogero A.E., Gambineri A., Vignozzi L., Prodam F., Aimaretti G., Linsalata G., Buralli S., Monzani F., Aversa A., Vettor R., Santini F., Vitti P., Gnessi L., Pagotto U., Giorgino F., Colao A., Lenzi A., Beccuti G., Biondi B., Cannavo S., Chiodini I., De Feudis G., Di Francesco S., Di Gregorio A., Fallo F., Foresta C., Giacchetti G., Granata R., Isidori A.M., Magni P., Maiellaro P., Caprino M.P., Pivonello R., Pofi R., Pontecorvi A., and Simeoli C.

Subjects
Weight loss, medicine.medical_specialty, Consensus, Ketogenic, Calorie, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Cardiovascular rehabilitation, Cardiovascular risk, Ketone bodies, Obesity, Type 2 diabetes, 030209 endocrinology & metabolism, Type 2 diabete, 03 medical and health sciences, Therapeutic approach, Settore MED/13, 0302 clinical medicine, Endocrinology, Metabolic Diseases, Medical, medicine, Milestone (project management), Humans, Intensive care medicine, Cardiovascular rehabilitation, Cardiovascular risk, Ketone bodies, Obesity, Type 2 diabetes, Weight loss, business.industry, Reducing, medicine.disease, Diet, 030220 oncology & carcinogenesis, Diet, Ketogenic, Diet, Reducing, Societies, Medical, medicine.symptom, Societies, business, Developed country, Ketone bodie, Ketogenic diet
Abstract

Background: Weight loss is a milestone in the prevention of chronic diseases associated with high morbility and mortality in industrialized countries. Very-low calorie ketogenic diets (VLCKDs) are increasingly used in clinical practice for weight loss and management of obesity-related comorbidities. Despite evidence on the clinical benefits of VLCKDs is rapidly emerging, some concern still exists about their potential risks and their use in the long-term, due to paucity of clinical studies. Notably, there is an important lack of guidelines on this topic, and the use and implementation of VLCKDs occurs vastly in the absence of clear evidence-based indications. Purpose: We describe here the biochemistry, benefits and risks of VLCKDs, and provide recommendations on the correct use of this therapeutic approach for weight loss and management of metabolic diseases at different stages of life.

Published
2019

17. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Hansel, K., Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli, Mc, Esposito, M, Ferrucci, S, Girolomoni, G, Offidani, A, Patrizi, A, Peris, K, Costanzo, A, Malara, G, Pellacani, G, Romanelli, M, Amerio, P, Cristaudo, A, Flori, Ml, Motolese, A, Betto, P, Patruno, C, Pigatto, P, Sirna, R, Stinco, G, Zalaudek, I, Bianchi, L, Boccaletti, V, Cannavò, Sp, Cusano, F, Lembo, S, Mozzillo, R, Gallo, R, Potenza, C, Rongioletti, F, Tiberio, R, Grieco, T, Micali, G, Persechino, S, Pettinato, M, Pucci, S, Savi, E, Stingeni, L, Romano, A, Argenziano, G, and Dupilumab Italian National Access Program (Dup-INAP, group).

Subjects
Male, Dermatitis, Severity of Illness Index, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Quality of life, Monoclonal, 80 and over, Humanized, Aged, 80 and over, Real-life, Atopic dermatitis, Middle Aged, Atopic dermatiti, Dupilumab, humanities, Treatment Outcome, atopic dermatitis, dupilumab, real-life, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Cohort study, atopic dermatiti, Adult, medicine.medical_specialty, Context (language use), Dermatology, Antibodies, Monoclonal, Humanized, Antibodies, Atopic, Dermatitis, Atopic, 03 medical and health sciences, Young Adult, Internal medicine, Severity of illness, medicine, Humans, Adverse effect, Aged, Retrospective Studies, 030203 arthritis & rheumatology, business.industry, Pruritus, Retrospective cohort study, medicine.disease, Quality of Life, business, Sleep
Abstract

Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.

Published
2021

18. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience

Author

Fargnoli M. C., Esposito M., Dapavo P., Parodi A., Rossi M., Tiberio R., Dastoli S., Offidani A. M., Argenziano G., Gisondi P., Lo Schiavo A., Loconsole F., Pella P., Bardazzi F., Cusano F., Gattoni M., Nacca M., Cannavo S. P., Pellegrini C., Costanzo A., Pertusi G., Stroppiana E., Gambardella A., Romano F., Sassetti C., Carpentieri A., Bellinato F., Burlando M., Graziola F., Sacchelli L., Campanati A., Ronza G., Fargnoli, M. C., Esposito, M., Dapavo, P., Parodi, A., Rossi, M., Tiberio, R., Dastoli, S., Offidani, A. M., Argenziano, G., Gisondi, P., Lo Schiavo, A., Loconsole, F., Pella, P., Bardazzi, F., Cusano, F., Gattoni, M., Nacca, M., Cannavo, S. P., Pellegrini, C., Costanzo, A., Pertusi, G., Stroppiana, E., Gambardella, A., Romano, F., Sassetti, C., Carpentieri, A., Bellinato, F., Burlando, M., Graziola, F., Sacchelli, L., Campanati, A., and Ronza, G.

Subjects
Adult, Male, medicine.medical_specialty, Brodalumab, Dermatology, Antibodies, Monoclonal, Humanized, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Patient satisfaction, Quality of life, Psoriasis Area and Severity Index, Psoriasis, Internal medicine, medicine, Humans, Adverse effect, Retrospective Studies, business.industry, Antibodies, Monoclonal, Retrospective cohort study, Dermatology Life Quality Index, Middle Aged, medicine.disease, Treatment Outcome, Infectious Diseases, 030220 oncology & carcinogenesis, Quality of Life, Female, business
Abstract

Background: Brodalumab was efficacious and safe in moderate-to-severe plaque-type psoriasis in the AMAGINE trials; published reports under real-life conditions are limited. Objectives: To evaluate the effectiveness and safety of brodalumab in patients with moderate-to-severe plaque-type psoriasis in a real-world setting. Methods: This observational, retrospective study enrolled adult patients (≥18years) with moderate-to-severe plaque-type psoriasis who underwent 24weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded. Results: Seventy-eight patients (mean age 47.9years, 71.8% male, average disease duration 16.8years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4weeks of treatment, decreasing further at weeks 12 and 24 (all P&nbsp

Published
2021

22. Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity

Author

Fatti, L, Cangiano, B, Vitale, G, Persani, L, Mantovani, G, Sala, E, Arosio, M, Maffei, P, Dassie, F, Mormando, M, Giampietro, A, Tanda, L, Masiello, E, Nazzari, E, Ferone, D, Corbetta, S, Passeri, E, Guaraldi, F, Grottoli, S, Cannavo, S, Torre, M, Soranna, D, Zambon, A, Cavagnini, F, Scacchi, M, Fatti L. M., Cangiano B., Vitale G., Persani L., Mantovani G., Sala E., Arosio M., Maffei P., Dassie F., Mormando M., Giampietro A., Tanda L., Masiello E. R., Nazzari E., Ferone D., Corbetta S., Passeri E., Guaraldi F., Grottoli S., Cannavo S., Torre M. L. T., Soranna D., Zambon A., Cavagnini F., Scacchi M., Fatti, L, Cangiano, B, Vitale, G, Persani, L, Mantovani, G, Sala, E, Arosio, M, Maffei, P, Dassie, F, Mormando, M, Giampietro, A, Tanda, L, Masiello, E, Nazzari, E, Ferone, D, Corbetta, S, Passeri, E, Guaraldi, F, Grottoli, S, Cannavo, S, Torre, M, Soranna, D, Zambon, A, Cavagnini, F, Scacchi, M, Fatti L. M., Cangiano B., Vitale G., Persani L., Mantovani G., Sala E., Arosio M., Maffei P., Dassie F., Mormando M., Giampietro A., Tanda L., Masiello E. R., Nazzari E., Ferone D., Corbetta S., Passeri E., Guaraldi F., Grottoli S., Cannavo S., Torre M. L. T., Soranna D., Zambon A., Cavagnini F., and Scacchi M.

Abstract

Purpose: Arthropathy is a common and disabling complication of acromegaly. Since in this condition radiological findings rarely correspond to functional impairment, we elected to quantify in a large cohort of acromegalic patients: the degree of motor disability compared with data from general population, the impact of joint involvement on quality of life and work productivity, and to look for associated factors. Methods: In 211 acromegalic patients, 131 with controlled disease and 80 with active disease, eight validated scales were used to evaluate the (i) prevalence and distribution of arthropathy, (ii) degree of motor disability and joint symptoms (VAS, AIMS symptoms and WOMAC), (iii) quality of life (AcroQoL and PASQ) and work capability (WPAI:GH) as consequences of joint complications. Results: Using the WOMAC questionnaire, for which population based normative values are available, a significantly higher prevalence and severity of motor disability was detected in acromegalics compared to the general population from literature. The results provided by the different questionnaires turned out to be highly concordant. All measures of motor disability correlated both with impaired quality of life and motor disability and were worse in females and in patients with higher BMI. Conclusions: The questionnaires VAS, AIMS symptoms, and WOMAC (this latter both as a whole and with its functionality subscale), with their scores, proved to be the most adequate tools to evaluate motor disability and its consequences on both quality of life and work productivity in acromegaly. Female gender and higher BMI are associated with worse articular symptoms.

Published
2019

25. Dupuytren Subungual Exostosis

Author

Vaccaro, M., Bartolomeo, L. D., and Cannavo, S. P.

Subjects
Nail Diseases, Osteochondroma, Humans, Bone Neoplasms, Toes, Exostoses
Published
2021

26. Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study

Author

Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, A., Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Gori N., Gallo R., Tonini G., Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, A., Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Gori N., Gallo R., and Tonini G.

Abstract

Adult atopic dermatitis (adult AD) is a systemic inflammatory disorder, whose relationship with immune-allergic and metabolic comorbidities is not well established yet. Moreover, treatment of mild-to-moderate and severe atopic dermatitis needs standardization among clinicians. The aim of this study was to evaluate the distribution of comorbidities, including metabolic abnormalities, rhinitis, conjunctivitis, asthma, alopecia and sleep disturbance, according to severity of adult AD, and describe treatments most commonly used by Italian dermatologists. Retrospective, observational, nationwide study of adult patients over a 2-year period was performed. Clinical and laboratory data were obtained through review of medical records of patients aged ≥ 18 years, followed in 23 Italian National reference centres for atopic dermatitis between September 2016 and September 2018. The main measurements evaluated were disease severity, atopic and metabolic comorbidities, treatment type and duration. Six-hundred and eighty-four adult patients with AD were included into the study. Atopic, but not metabolic conditions, except for hypertension, were significantly associated with having moderate-to-severe AD in young adult patients. Disease duration was significantly associated with disease severity. Oral corticosteroids and cyclosporine were the most widely used immunosuppressant. Our study seems confirm the close relationship between adult AD and other atopic conditions, further long-term cohort studies on patients affected by adult AD need to be performed to evaluate the complex relationship between adult AD disease severity and metabolic comorbidities.

Published
2021

27. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., Gallo R., Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., and Gallo R.

Abstract

Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.

Published
2021

29. Pruritus characteristics in a large Italian cohort of psoriatic patients

Author

Damiani, G., Cazzaniga, S., Conic, R. R. Z., Naldi, L., Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M. A., Baldassarre, M. A., Santoro, G., Vena, G. A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnu, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M. T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C. P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto di Luzio, G., Battarra, V. C., Farro, P., Plaitano, R., Micali, G., Musumeci, M. L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P. F., Amico, Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa lazzini, S., Bruscino, P., Agozzino, U. C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M. G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G. M., Serrai, M., Cannata, G., Campagnoli, A. M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F. M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M. C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A. S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D'Oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P. F., Padovan, C., Gonzalez Intchaurraga, M. A., Ladurner, J., Guarneri, B., Cannavo, S., Manfre, C., Borgia, F., Puglisi Guerra, A., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G. F., Taglioni, M., Lovati, C., Mercuri, S. R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G. F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Arico, M., Bongiorno, M. R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M. T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M. G., Lo Scocco, G., Niccoli, M. C., Brunasso Vernetti, A. M. G., Gaddoni, G., Resta, F., Casadio, M. C., Arcidiaco, M. C., Luvara, M. C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D'Agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigo, M., De Felice, C., Gubinelli, E., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P. G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M. A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappala, L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M. G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G. C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R. M., Silvestri, T., Girolomoni, G., Gisondi, P., Veller Fornasa, C., Trevisan, G. P., Damiani G., Cazzaniga S., Conic R.R.Z., Naldi L., Griseta V., Miracapillo A., Azzini M., Mocci L., Michelini M., Offidani A., Bernardini L., Campanati A., Ricotti G., Giacchetti A., Norat M., Gualco F., Castelli A., Cuccia A., Diana A., Roncarolo G., Belli M.A., Baldassarre M.A., Santoro G., Vena G.A., Lo Console F., Filotico R., Mastrandrea V., Brunetti B., Musumeci F., Carrabba E., Dal Mas P., Annicchiarico F., Benvegnu B., Spaziani G., Cusano F., Saletta Iannazzone S., Galluccio A., Pezza M., Marchesi L., Imberti G., Reseghetti A., Barbera C., Reggiani M., Lanzoni A., Patrizi A., Bardazzi F., Antonucci A., De Tommaso S., Wallnofer W., Ingannamorte F., Calzavara-Pinton P., Iannazzi S., Zane C., Capezzera R., Bassisi S., Rossi M.T., Altamura V., Vigl W., Nobile C., Aste N., Murgia S., Mugheddu C., Scuderi G., Baglieri F., Di Dio C., Cilioni Grilli E., Mastronardi C., Agnusdei C.P., Antrilli A., Aulisa L., Raimondo U., Scotto di Luzio G., Battarra V.C., Farro P., Plaitano R., Micali G., Musumeci M.L., Massimino D., Li Calzi M., La Greca S., Pettinato M., Sapienza G., Valenti G., De Giacomo P.F., Amico, Arcangeli F., Brunelli D., Ghetti E., Tulli A., Assi G., Amerio P., Laria G., Prestinari F., Spadafora S., Coppola M., Caresana G., Pezzarossa E., Felisi C., Donato L., Bertero M., Musso L., Pa lazzini S., Bruscino P., Agozzino U.C., Ottaviani M., Simoncini C., Virgili A., Osti F., Fabbri P., Volpi W., Caproni M., Lotti T., Prignano F., Buggiani G., Troiano M., Fenizi G., Altobella A., Amoruso A., Condello M., Goffredo A., Righini M.G., Alessandrini F., Satolli F., Zampetti M., Bertani E., Fossati S., Parodi A., Burlando M., Fiorucci C., Nigro A., Ghigliotti G., Massone L., Moise G.M., Serrai M., Cannata G., Campagnoli A.M., Daly M., Leporati C., Peila R., Filosa G., Bugatti L., Nicolini M., Nazzari G., Cestari R., Anastasio F., Larussa F.M., Pollice N., De Francesco F., Mazzocchetti G., Peris K., Fargnoli M.C., Di Cesare A., De Angelis L., Flati G., Biamonte A.S., Quarta G., Congedo M., Carcaterra A., Strippoli D., Fideli D., Marsili F., Celli M., Ceccarini M., Bachini L., D'Oria M., Schirripa V., De Filippi C., Martini P., Lapucci E., Mazzatenta C., Ghilardi A., Simonacci M., Bettacchi A., Gasco R., Zanca A., Battistini S., Dattola S., Vernaci R., Postorino F., Zampieri P.F., Padovan C., Gonzalez Intchaurraga M.A., Ladurner J., Guarneri B., Cannavo S., Manfre C., Borgia F., Puglisi Guerra A., Cattaneo A., Carrera C., Fracchiolla C., Mozzanica N., Prezzemolo L., Menni S., Lodi A., Martino P., Monti M., Mancini L., Sacrini F., Altomare G.F., Taglioni M., Lovati C., Mercuri S.R., Schiesari G., Giannetti A., Conti A., Lasagni C., Greco M., Ronsini G., Schianchi S., Fiorentini C., Niglietta S., Maglietta R., Padalino C., Crippa D., Pini M., Rossi E., Tosi D., Armas M., Ruocco V., Ayala F., Balato N., Gaudiello F., Cimmino G.F., Monfrecola G., Gallo L., Argenziano G., Fulgione E., Berruti G., Ceparano S., De Michele I., Giorgiano D., Leigheb G., Deledda S., Peserico A., Alaibac M., Piaserico S., Schiesari L., Dan G., Mattei I., Oro E., Arico M., Bongiorno M.R., Angileri R., Amato S., Todaro F., Milioto M., Bellastro R., Di Nuzzo S., De Panfilis G., Zanni M., Borroni G., Cananzi R., Brazzelli V., Lisi P., Stingeni L., Hansel K., Pierfelice V., Donelli S., Rastelli D., Gasperini M., Barachini P., Cecchi R., Bartoli L., Pavesi M., De Paola S., Corradin M.T., Ricciuti F., Piccirillo A., Viola L., Tataranni M., Mautone M.G., Lo Scocco G., Niccoli M.C., Brunasso Vernetti A.M.G., Gaddoni G., Resta F., Casadio M.C., Arcidiaco M.C., Luvara M.C., Albertini G., Di Lernia V., Guareschi E., Catrani S., Morri M., De Simone C., D'Agostino M., Agostino I., Calvieri S., Cantoresi F., Richetta A., Sorgi P., Carnevale C., Nicolucci F., Berardesca E., Ardigo M., De Felice C., Gubinelli E., Talamonti M., Camplone G., Cruciani G., Riccardi F., Barbati R., Zumiani G., Pagani W., Malagoli P.G., Pellicano R., Donadio D., Di Vito C., Cottoni F., Montesu M.A., Pirodda C., Addis G., Marongiu P., Farris A., Cacciapuoti M., Verrini A., Desirello G., Gnone M., Fimiani M., Pellegrino M., Castelli G., Zappala L., Sesana G., Ingordo V., Vozza E., Di Giuseppe D., Fasciocco D., Nespoli P., Papini M., Cicoletti M., Bernengo M.G., Ortoncelli M., Bonvicino A., Capella G., Doveil G.C., Forte M., Peroni A., Salomone B., Savoia P., Pippione M., Zichichi L., Frazzitta M., De Luca G., Tasin L., Simonetto D., Ros S., Trevisan G., Patamia M., Miertusova S., Patrone P., Frattasio A., Piccirillo F., La Spina S., Di Gaetano L., Marzocchi V., Motolese A., Venturi C., Gai F., Pasquinucci S., Bellazzi R.M., Silvestri T., Girolomoni G., Gisondi P., Veller Fornasa C., and Trevisan G.P.

Subjects
Male, Cross-sectional study, Severity of Illness Index, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Risk Factors, education, itch, pruritus, psoriasis, pustular psoriasis, treatment, Adolescent, Adult, Cross-Sectional Studies, Educational Status, Facial Dermatoses, Female, Foot Dermatoses, Genitalia, Hand Dermatoses, Humans, Italy, Middle Aged, Pruritus, Psoriasis, Registries, Sex Factors, Young Adult, Epidemiology, Young adult, skin and connective tissue diseases, Settore MED/33 - MALATTIE APPARATO LOCOMOTORE, Infectious Diseases, 030220 oncology & carcinogenesis, Cohort, PRURITIS EPIDEMIOLOGY, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Cohort study, medicine.medical_specialty, PSORIAS, Dermatology, Article, 03 medical and health sciences, Pharmacotherapy, Settore MED/35, Severity of illness, medicine, business.industry, medicine.disease, Pruritus,Itch sensation, business
Abstract

Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10802 patients, with a mean age 48.8±14.3years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and very severe in 13.7%. Higher itch intensity was associated with female gender, lower educational attainment compared to university degree, pustular psoriasis, psoriasis on the head, face, palmoplantar areas, folds and genitalia, more severe disease, disease duration

Published
2019

30. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience

Author

Lacarrubba, F., Dini, V., Napolitano, M., Venturini, M., Caposiena Caro, D. R., Molinelli, E., Passoni, E., Monfrecola, G., Argenziano, G., Berti, E., Bianchi, L., Calzavara Pinton, P., Cannavo, S. P., Costanzo, A., Donini, M., Fabbrocini, G., Fierro, M. T., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Peris, K., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Solivetti, F., Lacarrubba, F., Dini, V., Napolitano, M., Venturini, M., Caposiena Caro, D. R., Molinelli, E., Passoni, E., Monfrecola, G., Argenziano, G., Berti, E., Bianchi, L., Calzavara Pinton, P., Cannavo, S. P., Costanzo, A., Donini, M., Fabbrocini, G., Fierro, M. T., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Peris, K., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Solivetti, F., Lacarrubba F., Dini V., Napolitano M., Venturini M., Caposiena Caro D.R., Molinelli E., Passoni E., Monfrecola G., Argenziano G., Berti E., Bianchi L., Calzavara Pinton P., Cannavo S.P., Costanzo A., Donini M., Fabbrocini G., Fierro M.T., Micali G., Offidani A., Parodi A., Patrizi A., Pellacani G., Peris K., Pimpinelli N., Potenza C., Romanelli M., Rongioletti F., and Solivetti F.

Subjects
Adult, Male, medicine.medical_specialty, Standard of care, Dermatology, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Disease severity, Retrospective Studie, Internal medicine, medicine, Humans, Hidradenitis suppurativa, Radiation treatment planning, Grading (tumors), Physical Examination, Retrospective Studies, Ultrasonography, Settore MED/35 - Malattie Cutanee e Veneree, business.industry, Ultrasound, Retrospective cohort study, Middle Aged, medicine.disease, Hidradenitis Suppurativa, Infectious Diseases, Ultrasound Working Group experience, 030220 oncology & carcinogenesis, Female, business, Human
Abstract

Background: Ultrasound (US) is a real-time non-invasive technique that has been demonstrated to support an early diagnosis and a more precise assessment of hidradenitis suppurativa (HS). Objectives: To compare the clinical and US evaluation of a series of HS patients. Methods: 434 HS patients (259 F, 175 M; mean age 33.82 ±13.31 years) observed across 19 Italian dermatology centres [members of the Italian Ultrasound Working Group (IUWG)] were enrolled in a retrospective study. Clinical staging was obtained by the Hidradenitis Suppurativa Physician's Global Assessment score (HS-PGA), while the ultrasonographic staging was determined by the US HS-PGA, based on the same scores as clinical HS-PGA but performed with the aid of US. Results: At the end of the study, the mean clinical and US HS-PGA scores were 2.70 and 2.92, respectively. Direct comparison of clinical and ultrasonographic assessment revealed that a higher proportion of patients was classified as having moderate and very severe disease by US. In particular, 117 patients (26.96%) had a worse classification by US HS-PGA compared to clinical assessment. Conclusion: Our findings confirm that the use of clinical grading only to assess HS severity may underestimate the real disease severity. US examination can be considered an essential non-invasive imaging tool available to dermatologists for a more accurate diagnosis, staging, treatment planning and monitoring of HS and should be included in the pathway to an optimal standard of care of HS.

Published
2019

32. Oxidative stress involvement in urticaria

Author

Cannavo, S. P., Riso, G., Di Salvo, E., Casciaro, M., Giuffrida, R., Minciullo, P. L., Guarneri, F., Nettis, E., and Gangemi, S.

Subjects
Oxidative Stress, inflammation, interleukins, oxidative stress, ROS, skin, urticaria, Urticaria, Chronic Disease, Humans
Published
2020

35. Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis

Author

Scala, E., Megna, M., Amerio, P., Argenziano, G., Babino, G., Bardazzi, F., Bianchi, L., Caldarola, Giacomo, Campanati, A., Cannavo, S. P., Chiricozzi, Andrea, Conti, A., Damiani, G., Dapavo, P., De Simone, C., Esposito, M., Fabbrocini, G., Fargnoli, M. C., Ferrara, F., Fidanza, R., Gualdi, G., Guarneri, C., Hansel, K., Malagoli, P., Malara, G., Micali, G., Mugheddu, C., Musumeci, M. L., Odorici, G., Offidani, A., Pescitelli, L., Prignano, F., Raimondo, A., Ribero, S., Rongioletti, F., Stingeni, L., Trifiro, C., Zanframundo, S., Balato, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Scala, E., Megna, M., Amerio, P., Argenziano, G., Babino, G., Bardazzi, F., Bianchi, L., Caldarola, Giacomo, Campanati, A., Cannavo, S. P., Chiricozzi, Andrea, Conti, A., Damiani, G., Dapavo, P., De Simone, C., Esposito, M., Fabbrocini, G., Fargnoli, M. C., Ferrara, F., Fidanza, R., Gualdi, G., Guarneri, C., Hansel, K., Malagoli, P., Malara, G., Micali, G., Mugheddu, C., Musumeci, M. L., Odorici, G., Offidani, A., Pescitelli, L., Prignano, F., Raimondo, A., Ribero, S., Rongioletti, F., Stingeni, L., Trifiro, C., Zanframundo, S., Balato, A., and Chiricozzi A. (ORCID:0000-0002-6739-0387)

Abstract

Background Knowledge regarding differences in care for psoriatic patients is limited. The aim of this study was to investigate factors influencing prescription of systemic treatments for patients with psoriasis with a special focus on socioeconomic factors. Methods and findings This was a non-interventional, cross-sectional study, conducted in 18 Italian University and/ or hospital centers with psoriasis-specialized units. Questionnaires evaluating demographic and socioeconomic characteristics were administered to participants. Overall, 1880 consecutive patients affected by mild-to-severe psoriasis were recruited. Univariate and multivariable logistic regression analyses of systemic therapy prescription, with a special focus on biologics, accounting for the above mentioned characteristics were performed. Our analysis showed that all analyzed patients' characteristics were significantly associated with biological therapy compared to non-biological systemic one. Particularly, women were less likely to receive biologics than men (OR = 0.66; 95% CI, 0.57-0.77). Elderly patients (≥65 years) and subjects with a BMI ≥30 had lower odds to receive biologics respect to adults (≥35-64 years) (OR = 0.33; 95% CI, 0.25-0.40), and subjects with BMI≥25<30 (OR = 0.64; 95% CI, 0.53-0.77), respectively. Northern and Southern patients were both less likely to receive biologics than Central patients (OR = 0.75; 95% CI, 0.63-0.89, and OR = 0.56; 95% CI,0.47-0.68, respectively). Lower economic profile and never reading books were both associated with decreased odds of receiving biological therapy. Conclusions This study shows that sex, age, comorbidities, and socioeconomic characteristics influence the prescription of systemic treatments in psoriasis, highlighting that there are still unmet needs influencing the therapeutic decision-making process that have to be addressed.

Published
2020

36. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author

Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), and De Simone C. (ORCID:0000-0002-0898-0045)

Abstract

N/A

Published
2020

37. Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients

Author

De Simone, Clara, Calabrese, L., Balato, A., Cannavo, S. P., Dattola, Carmelo Alberto, Esposito, M., Fargnoli, Maria Concetta, Giuffrida, R., Hansel, K., Musumeci, M. L., Napolitano, M., Offidani, A., Parodi, A., Patriatrizi, A., Peris, Ketty, Radi, G., Venturini, M., Prignano, F., De Simone C. (ORCID:0000-0002-0898-0045), Dattola A., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), De Simone, Clara, Calabrese, L., Balato, A., Cannavo, S. P., Dattola, Carmelo Alberto, Esposito, M., Fargnoli, Maria Concetta, Giuffrida, R., Hansel, K., Musumeci, M. L., Napolitano, M., Offidani, A., Parodi, A., Patriatrizi, A., Peris, Ketty, Radi, G., Venturini, M., Prignano, F., De Simone C. (ORCID:0000-0002-0898-0045), Dattola A., Fargnoli M. C., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Psoriasis is a common, chronic inflammatory disease with a multifactorial pathogenesis. Mean age at presentation of psoriasis is 28 years in women, which is almost the height of fertility age. Since women of childbearing potential represent a significant proportion of psoriatic patients, the impact of psoriasis and its treatment on fertility, pregnancy, and breastfeeding should be highlighted for a proper management. Therefore, when approaching to a psoriatic woman of childbearing age, Healthcare Providers should be adequately informed and ready to provide the patients with answers to the most frequently asked questions. The Italian Society of Dermatology and Venereology (SID eMaST) has fostered a Task Force named "Psoriasis in Women of Childbearing Age" which is composed by a group of Italian female dermatologists with a high expertise in psoriasis treatment. The aims of the Task Force are to increase awareness of the disease and its treatment in patients of childbearing age among both dermatologists and women affected by psoriasis and to encourage counselling on family planning. With the aim of providing a real support for the proper management of the delicate journey to motherhood, the Italian Task Force has published two different informative booklets addressed to patients and dermatologists which focus on the main issues regarding psoriasis in women of childbearing age.

Published
2020

38. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Stingeni, L., Caruso, C., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., Gallo R., Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Stingeni, L., Caruso, C., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., and Gallo R.

Abstract

na

Published
2020

39. Hidradenitis suppurativa and adalimumab in the COVID-19 era

Author

Marzano, A. V., Moltrasio, C., Genovese, Giannicola, Muratori, S., Dapavo, P., Fabbrocini, G., Patrizi, A., Sechi, A., Micali, G., Pellegrino, Maria Gabriella, Gisondi, P., Dini, Veronica, Bianchi, L., Fania, L., Offidani, A., Prignano, F., Atzori, L., Miraglia, E., Cannavo, S. P., Bettoli, V., Stingeni, L., Balestri, R., Venturini, M., Peris, Ketty, Genovese G., Pellegrino M., Dini V., Peris K. (ORCID:0000-0002-5237-0463), Marzano, A. V., Moltrasio, C., Genovese, Giannicola, Muratori, S., Dapavo, P., Fabbrocini, G., Patrizi, A., Sechi, A., Micali, G., Pellegrino, Maria Gabriella, Gisondi, P., Dini, Veronica, Bianchi, L., Fania, L., Offidani, A., Prignano, F., Atzori, L., Miraglia, E., Cannavo, S. P., Bettoli, V., Stingeni, L., Balestri, R., Venturini, M., Peris, Ketty, Genovese G., Pellegrino M., Dini V., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

na

Published
2020

40. ESE audit on management of adult growth hormone deficiency in clinical practice

Author

Martel-Duguech, Luciana, primary, Jorgensen, Jens Otto L, additional, Korbonits, Márta, additional, Johannsson, Gudmundur, additional, Webb, Susan M, additional, _, _, additional, Adamidou, F, additional, Mintziori, G, additional, Arosio, M, additional, Giavoli, C, additional, Badiu, C, additional, Boschetti, M, additional, Ferone, D, additional, Ricci Bitti, S, additional, Brue, T, additional, Albarel, F, additional, Cannavo, S, additional, Martino, G, additional, Cotta, O R, additional, Carvalho, D, additional, Salazar, D, additional, Christ, E, additional, Debono, M, additional, Dusek, T, additional, García, R, additional, Ghigo, E, additional, Gasco, V, additional, Goth, M I, additional, Olah, D, additional, Kovacs, L, additional, Höybye, C, additional, Kocjan, T, additional, Mlekuš Kozamernik, K, additional, Kužma, M, additional, Medic Stojanoska, M, additional, Novak, A, additional, Miličević, T, additional, Pekic, S, additional, Milijic, D, additional, Perez Luis, J, additional, Pico, A, additional, Preda, V, additional, Raverot, G, additional, Borson-Chazot, F, additional, Rochira, V, additional, Monzani, M L, additional, Sandahl, K, additional, Tsagarakis, S, additional, Mitravela, V, additional, Zacharieva, S, additional, Zilatiene, B, additional, and Verkauskiene, R, additional

Published
2021
Full Text
View/download PDF

41. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, M. C., primary, Esposito, M., additional, Ferrucci, S., additional, Girolomoni, G., additional, Offidani, A., additional, Patrizi, A., additional, Peris, K., additional, Costanzo, A., additional, Malara, G., additional, Pellacani, G., additional, Romanelli, M., additional, Amerio, P., additional, Cristaudo, A., additional, Flori, M. L., additional, Motolese, A., additional, Betto, P., additional, Patruno, C., additional, Pigatto, P., additional, Peccianti, C., additional, Stinco, G., additional, Zalaudek, I., additional, Bianchi, L., additional, Boccaletti, V., additional, Cannavo, S. P., additional, Cusano, F., additional, Lembo, S., additional, Mozzillo, R., additional, Gallo, R., additional, Potenza, C., additional, Rongioletti, F., additional, Tiberio, R., additional, Grieco, T., additional, Micali, G., additional, Persechino, S., additional, Pettinato, M., additional, Pucci, S., additional, Stingeni, L., additional, Caruso, C., additional, and Argenziano, G., additional

Published
2020
Full Text
View/download PDF

43. Contribution to the knowledge of Mediterranean wetland biodiversity: Plant communities of the Aquila Lake (Calabria, Southern Italy)

Author

Spampinato G., Sciandrello S., Del Galdo G.G., Puglisi M., Tomaselli V., Cannavo S., and Musarella C.M.

Subjects
Cluster analysis, Italy, Phytosociology, Reggio Calabria, Wetland vegetation
Abstract

As part of researches undertaken on the aquatic and marsh vegetation of southern Italy, a study on the Aquila Lake, a small lake basin in southern Calabria near Rosarno (RC), is here presented. Overall, 86 phytosociological relevés were carried out. The phytosociological study allowed the identification of several aquatic and marsh phytocoenoses, many of which not yet known for the region. They are referable to the following 8 classes: Lemnetea minoris R. Tx. ex O. Bolòs & Masclans 1955, Potametea pectinati R.Tx. & Preising 1942, Phragmito australis-Magnocaricetea elatae Klika in Klika & Novák 1941, Agrostietea stoloniferae Oberdorfer 1983, Galio aparines-Urticetea dioicae Passarge ex Kopecký 1969, Molinio-Arrhenatheretea Tüxen 1937, Salici purpureae-Populetea nigrae Rivas-Martínez & Cantó ex Rivas-Martínez et al. 2001, Querco roboris-Fagetea sylvaticae Br.-Bl. & Vlieger in Vlieger 1937. A peculiar marsh vegetation is the Cladietum marisci Allorge 1922 ex Zobrist 1935 (habitat of Community interest, according to the EEC directive 43/92 - 7210 *Calcareous ferns with Cladium mariscus and species of the Caricion davallianae"). In the Aquila Lake, some rare aquatic plant communities highlight the importance of this biotope for biodiversity conservation. In particular, we found the pleustophytic associations Lemno-Spirodeletum polyrhizae Koch 1954, Lemno minoris-Hydrocharitetum morsus-ranae Passarge 1978 and the aquatic rooted vegetation of Nymphaeetum albae Vollm. 1947. Despite the heavy pressures on this area, the biotope harbours a well-differentiated and structured aquatic and marsh vegetation that allows the presence of a rich bird life, both sedentary and migratory. The area, privately owned, is not protected; hunting and fishing are practiced and water is pumped for irrigation with negative consequences on the integrity of the entire aquatic ecosystem. Because of its naturalistic peculiarities and its remarkable biodiversity, this biotope certainly deserves more attention and should be proposed as a protected area.

Published
2019

44. Physician–patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy

Author

Neri, L., Peris, K., Longo, C., Calvieri, S., Frascione, P., Parodi, A., Eibenschuz, L., Bottoni, U., Pellacani, G., Ayala, F., Quaglino, P., Cannavo, S., Rubegni, P., Ferreli, C., Girolomoni, G., Bongiorno, M. R., Potenza, C., Micali, G., Pimpinelli, N., Romanelli, M., Stanganelli, I., Bonamonte, D., Peserico, A., Fargnoli, M. C., Pinton, P. C., Costanzo, D., Cantisani, C., Borsari, S., Ricci, F., Izzi, S., Chiara, F., Cozzani, E., Carboni, A., Amoruso, G. F., Dastoli, S., Scalvenzi, M., Deboli, T., Francesco, B., Casari, A., Nami, N., Camilla Delle Vedove, C. S., Viola, L., La Carrubba, F., Grandi, V., Dini, V., Mazzoni, L., Vestita, M. L., Fabiano, A., Zane, C., Orsini, D., Neri, L., Peris, K., Longo, C., Calvieri, S., Frascione, P., Parodi, A., Eibenschuz, L., Bottoni, U., Pellacani, G., Ayala, Fabio, Quaglino, Pietro, Cannavò, Serafinella, Rubegni, Pietro, Ferreli, Caterina, Girolomoni, Gianpiero, Bongiorno, Maria Rita, Potenza, Concetta, Micali, Giuseppe, Pimpinelli, Nicola, Romanelli, Marco, Stanganelli, Ignazio, Bonamonte, Domenico, Peserico, Andrea, Fargnoli, Maria Concetta, Pinton, Piergiacomo Calzavara, Costanzo, Domenico, Cantisani, Carmen, Borsari, Stefania, Ricci, Francesco, Izzi, Sara, Chiara, Franceschini, Cozzani, Emanuele, Carboni, Anna, Amoruso, Giuseppe F., Dastoli, Stefano, Scalvenzi, Massimiliano, Deboli, Tommaso, Francesco, Borgia, Casari, Alice, Nami, Nicolò, Camilla Delle Vedove, Chiara Sabbatini, Viola, La, La Carrubba, Francesco, Grandi, Vieri, Dini, Valentina, Mazzoni, Laura, Vestita, Michelangelo la, Fabiano, Antonella, Zane, Cristina, and Orsini, Diego

Subjects
Male, infectious diseases, actinic keratoses, Diclofenac, Actinic, topical field‐directed therapy, Anti-Inflammatory Agents, Antineoplastic Agents, Administration, Cutaneous, Medication Adherence, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Diterpenes, Drug Eruptions, Female, Humans, Imiquimod, Italy, Keratosis, Actinic, Longitudinal Studies, Middle Aged, Patient Reported Outcome Measures, Prospective Studies, Quality of Life, Communication, Patient Satisfaction, Physician-Patient Relations, Infectious Diseases, 80 and over, actinic keratose, treatment, Keratosis, Cutaneous, Administration, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Non-Steroidal
Abstract

Background: Patients with multiple actinic keratoses (AKs) should be treated with field-directed therapy. Such treatments challenge patients’ adherence due to out-of-pocket costs, length of treatment and severity of local skin reactions (LSRs). Effective physician–patient communication (PPC) may buffer therapy-related distress, thus improving quality of life, treatment satisfaction and adherence. Objectives: We evaluated the interplay between PPC, LSR intensity (safety) and lesion clearance rates (effectiveness) on treatment satisfaction, quality of life and treatment adherence among patients with multiple AKs receiving topical field-directed therapies. Methods: In this observational, multicentre, longitudinal, cohort study, we included 1136 adult patients with discrete, clinically detectable, visible, multiple (three or more lesions in a 25cm2 area), Grade I/II AKs, for whom the attending dermatologist has prescribed treatment with a topical field-directed therapy. We matched self-reported data and medical information recorded by dermatologists in standard clinical forms. Patients were followed up at two time points (T1: 8days; T2: 25–30days). Results: Most patients were elderly, married, men with poor socio-economic status and multiple lesions of the scalp or face. The majority (n=961) had a prescription of ingenol mebutate (IMB) and 175 received either diclofenac 3% in hyaluronic acid (DHA) or imiquimod 5% (IMQ). Clearance rate at 1month was 84%. Most patients felt very supported (n=819, 73%) and rated dermatologist's explanations very clear (n=608, 54%). Treatment satisfaction (effectiveness and convenience scales) increased along the follow-up, especially for those on IMB (Δpre-post=−4.00; other: Δpre-post=−0.25; interaction P&nbsp

Published
2019

46. Genome-wide DNA methylation analysis in two different types of pituitary tumors

Author

Polito, F., D Argennio, V., Capasso, M., Ferrau, F., Di Maggio, F., Oteri, R., Angileri, F., Di Giorgio, R., Esposito, F., Asmundo, A., Lucio Pastore, Cannavo, S., Aguennouz, M., Polito, F, D'Argennio, V, Capasso, M, Ferraù, F, Di Maggio, F, Oteri, R, Flavio Angileri, Filippo, Di Giorgio, Rosamaria, Esposito, Felice, Asmundo, A, Pastore, L, Cannavò, Salvatore, and Aguennouz, M'Hammed

Published
2019

47. Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis)

Author

Damiani, G, Calzavara-Pinton, P, Stingeni, L, Hansel, K, Cusano, F, Pigatto, P, Agostinelli, D, Albertazzi, D, Angelini, G, Angerosa, F, Arigliano, P, Assalve, D, Ayala, F, Barbagallo, T, Belloni-Fortina, A, Berta, M, Biale, C, Bianchi, L, Biasini, I, Boccaletti, V, Bonamonte, D, Borghi, A, Bragazzi, N, Brambilla, L, Bressan, M, Brunasso, A, Bruni, F, Bruni, P, Caccavalle, S, Calogiuri, G, Cannavo, S, Carugno, A, Cataldi, I, Chiarelli, G, Cirla, A, Corazza, M, Cossutta, M, Cova, L, Cristaudo, A, Danese, P, Dal Canton, M, Depita, O, De Salvo, P, Donini, M, Fantini, F, Ferrucci, S, Flori, M, Fontana, E, Foti, C, Francalci, S, Frasin, L, Gallo, R, Gasparini, G, Gola, M, Gravante, M, Guarnieri, F, Guastaferro, D, Ingordo, V, Lauriola, M, Leghissa, P, Lisi, P, Lombardi, P, Lorenzini, M, Malara, G, Magrini, L, Marone, G, Martina, E, Mascagni, P, Chiari, M, Meligeni, L, Melino, M, Miccio, L, Milanesi, N, Molinu, A, Monfrecola, G, Morelli, P, Motolese, A, Musumeci, M, Naldi, L, Napolitano, M, Nasca, M, Pacifico, A, Paganini, P, Papini, M, Pasolini, G, Patruno, C, Pellegrino, M, Peroni, A, Peserico, A, Piras, V, Pugliese, A, Raponi, F, Raviolo, P, Rebora, A, Recchia, G, Riva, F, Romita, P, Rossi, M, Ruggieri, M, Saggiorato, F, Sartorelli, P, Schena, D, Schettino, A, Spano, G, Stinchi, C, Tasin, L, Tramontana, M, Taddei, L, Valsecchi, R, Russo, F, Vascellaro, A, Venturini, M, Vincenzi, C, Virgili, A, Zucca, M, Pigatto, PDM, Arigliano, PL, Bragazzi, NL, Brunasso, AMG, Cannavo, SP, Cirla, AM, DePita, O, Ferrucci, SM, Flori, ML, Frasin, LA, Ingordo, V., Lauriola, MM, Chiari, Matteini M, Musumeci, ML, Nasca, MR, Raviolo, PD, Recchia, GP, Valsecchi, RE, Damiani, G, Calzavara-Pinton, P, Stingeni, L, Hansel, K, Cusano, F, Pigatto, P, Agostinelli, D, Albertazzi, D, Angelini, G, Angerosa, F, Arigliano, P, Assalve, D, Ayala, F, Barbagallo, T, Belloni-Fortina, A, Berta, M, Biale, C, Bianchi, L, Biasini, I, Boccaletti, V, Bonamonte, D, Borghi, A, Bragazzi, N, Brambilla, L, Bressan, M, Brunasso, A, Bruni, F, Bruni, P, Caccavalle, S, Calogiuri, G, Cannavo, S, Carugno, A, Cataldi, I, Chiarelli, G, Cirla, A, Corazza, M, Cossutta, M, Cova, L, Cristaudo, A, Danese, P, Dal Canton, M, Depita, O, De Salvo, P, Donini, M, Fantini, F, Ferrucci, S, Flori, M, Fontana, E, Foti, C, Francalci, S, Frasin, L, Gallo, R, Gasparini, G, Gola, M, Gravante, M, Guarnieri, F, Guastaferro, D, Ingordo, V, Lauriola, M, Leghissa, P, Lisi, P, Lombardi, P, Lorenzini, M, Malara, G, Magrini, L, Marone, G, Martina, E, Mascagni, P, Chiari, M, Meligeni, L, Melino, M, Miccio, L, Milanesi, N, Molinu, A, Monfrecola, G, Morelli, P, Motolese, A, Musumeci, M, Naldi, L, Napolitano, M, Nasca, M, Pacifico, A, Paganini, P, Papini, M, Pasolini, G, Patruno, C, Pellegrino, M, Peroni, A, Peserico, A, Piras, V, Pugliese, A, Raponi, F, Raviolo, P, Rebora, A, Recchia, G, Riva, F, Romita, P, Rossi, M, Ruggieri, M, Saggiorato, F, Sartorelli, P, Schena, D, Schettino, A, Spano, G, Stinchi, C, Tasin, L, Tramontana, M, Taddei, L, Valsecchi, R, Russo, F, Vascellaro, A, Venturini, M, Vincenzi, C, Virgili, A, Zucca, M, Pigatto, PDM, Arigliano, PL, Bragazzi, NL, Brunasso, AMG, Cannavo, SP, Cirla, AM, DePita, O, Ferrucci, SM, Flori, ML, Frasin, LA, Ingordo, V., Lauriola, MM, Chiari, Matteini M, Musumeci, ML, Nasca, MR, Raviolo, PD, Recchia, GP, and Valsecchi, RE

Abstract

Atopic dermatitis (AD) therapeutic approach calls for a long-term treatment. Treatment options for AD have recently undergone a revolutionary change by the introduction of the first biologic drug. Availability in daily practice of the last version of international AD guidelines, taking peculiarities of the country into account, can contribute to good clinical practice in Italy. To adapt European Dermatology Forum (EDF) guidelines for AD to the Italian medical–legal context, the EDF guidelines were assessed independently by two independent Italian renowned experts in the field and further integrated with articles published and systematically reviewed before May 2019. The first draft was collegially corrected and updated by the members of the SIDEMAST, ADOI, and SIDAPA. Recommendation levels (A; B; C; D) were graded based on the evidence levels (1–4). The adapted guidelines presented here focus on topical and systemic therapies in AD patients, both children and adults. As opposed to previous Italian guidelines, they include indications about biologics. New relevant evidence available from very recent literature and peculiarities of the Italian medical and legal context have been integrated in the revision process. If compared to general guidelines for AD not adapted to a specific national and cultural context, a revision for specific Italian needs is now available: It comprises the option of implementing the new biologic treatments and is likely to provide an important contribution to the improvement of clinical practice in Italy. Cooperation between patients, dermatologists, allergologists, and pediatricians remains mandatory in AD management. The authors of the present revision recommend an update of the Italian guidelines to be performed at least every second year.

Published
2019

48. Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients

Author

Fabbrocini, G., Marasca, C., Megna, M., Peris, Ketty, Amerio, P., Ardigo, M., Argenziano, G., Berti, Emanuele, Bettoli, V., Bianchi, L., Bongiorno, M. R., Cacciapuoti, S., Calzavara Pinton, P., Cannavo, S. P., Costanzo, Rosa Maria Alba, Cusano, F., Donini, M., Fierro, M. T., Lo Re, M., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Pigatto, P., Pimpinelli, N., Potenza, C., Romanelli, Margherita, Rongioletti, F., Stingeni, L., Peris K. (ORCID:0000-0002-5237-0463), Berti E., Costanzo A., Romanelli M., Fabbrocini, G., Marasca, C., Megna, M., Peris, Ketty, Amerio, P., Ardigo, M., Argenziano, G., Berti, Emanuele, Bettoli, V., Bianchi, L., Bongiorno, M. R., Cacciapuoti, S., Calzavara Pinton, P., Cannavo, S. P., Costanzo, Rosa Maria Alba, Cusano, F., Donini, M., Fierro, M. T., Lo Re, M., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Pigatto, P., Pimpinelli, N., Potenza, C., Romanelli, Margherita, Rongioletti, F., Stingeni, L., Peris K. (ORCID:0000-0002-5237-0463), Berti E., Costanzo A., and Romanelli M.

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease characterized by a significant impairment of patients’ quality of life (QoL). It has been recently found that clinical severity of HS does not correlate well with QoL. Therefore, it is important to enhance the evaluation of severity considering the disease burden on QoL. Recently, a new graphical tool able to better describe HS burden, the so-called HIDRAdisk, has been introduced. Objective: To investigate the utility of HIDRAdisk in clinical practice before and after treatment and to analyse whether specific factors such as age and gender may influence the outcomes in patients with moderate-to-severe HS. Methods: A single-centre retrospective study on 24 patients (13F/11M, mean age 38 ± 15 years) with moderate-to-severe HS was performed. Clinical data (disease severity and quality of life) were collected at baseline and after 12 weeks of adalimumab. Results: HIDRAdisk showed significantly better improvements in males (69.8 ± 6.2–49.6 ± 10.8) compared to females (80.7 ± 6.0–72.3 ± 6.7), P <0.001. A significant correlation was found in the total population between HS severity values measured through the modified Sartorius score (mSS) and QoL measured through HIDRAdisk. As regards the relationship between disease outcomes and age, a trend for better HIDRAdisk outcomes in younger patients (<40 years) compared to older ones was observed. Conclusions: HIDRAdisk appears as a complete and informative tool which can easily measure the global burden of HS, guiding treatment choice and evaluating its efficacy.

Published
2019

49. Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light

Author

Ribero, S., Dapavo, P., Casalegno, C., Alaibac, M., Argenziano, G., Arpaia, N. G., Bagnoni, G., Berti, Emanuele, Bianchi, L., Bianchini, D., Calzavara Pinton, P., Cannavo, S. P., Congedo, Maria Teresa, Corrao, S., Costanzo, Rosa Maria Alba, Cusano, F., Dattola, S., Dattoli, S., Deledda, S., Donini, M., Fabbrocini, G., Teresa Fierro, M., Foti, C., Galluccio, A. G., Gatti, A., Rene Girardelli, C., Girolomoni, G., Lemme, G., Malagoli, P., Malara, G., Mercuri, S. R., Micali, G., Montesu, M. A., Offidani, A., Papini, M., Parodi, A., Patrizi, A., Pellacani, G., Peris, Ketty, Piccirillo, A., Pigatto, P., Pimpinelli, N., Potenza, C., Provenzano, Katia Elisabetta, Romanelli, Margherita, Rongioletti, F., Savoia, P., Simonacci, Matteo, Sirna, R., Stinco, G., Valenti, Gianfranco, Zalaudek, Iris, Berti E., Congedo M., Costanzo A., Peris K. (ORCID:0000-0002-5237-0463), Provenzano E., Romanelli M., Simonacci M., Valenti G., Zalaudek I., Ribero, S., Dapavo, P., Casalegno, C., Alaibac, M., Argenziano, G., Arpaia, N. G., Bagnoni, G., Berti, Emanuele, Bianchi, L., Bianchini, D., Calzavara Pinton, P., Cannavo, S. P., Congedo, Maria Teresa, Corrao, S., Costanzo, Rosa Maria Alba, Cusano, F., Dattola, S., Dattoli, S., Deledda, S., Donini, M., Fabbrocini, G., Teresa Fierro, M., Foti, C., Galluccio, A. G., Gatti, A., Rene Girardelli, C., Girolomoni, G., Lemme, G., Malagoli, P., Malara, G., Mercuri, S. R., Micali, G., Montesu, M. A., Offidani, A., Papini, M., Parodi, A., Patrizi, A., Pellacani, G., Peris, Ketty, Piccirillo, A., Pigatto, P., Pimpinelli, N., Potenza, C., Provenzano, Katia Elisabetta, Romanelli, Margherita, Rongioletti, F., Savoia, P., Simonacci, Matteo, Sirna, R., Stinco, G., Valenti, Gianfranco, Zalaudek, Iris, Berti E., Congedo M., Costanzo A., Peris K. (ORCID:0000-0002-5237-0463), Provenzano E., Romanelli M., Simonacci M., Valenti G., and Zalaudek I.

Abstract

Background: Hidradenitis suppurativa is an inflammatory skin disease that presents a recurrence of painful and suppurating lesions in the apocrine gland-bearing regions, with a strong impact on the patients’ life quality. Despite its peculiar presentation, early forms are often underestimated by patients and this would inevitably result in late diagnosis and delayed therapy. Objectives: Improved communication around the disease could facilitate self-diagnosis and a quicker response from healthcare practitioners, especially in this moment when we dispose of effective treatment against this disease. Methods: A HS awareness campaign was conducted for 2 years with the help of a media agency and a patients’ association. Results: Results confirm that a better communication has a strong impact on the disease awareness. Conclusions: This paper demonstrates that the more this disease awareness is carried on, the more quick, effective and efficient the patient's management could be.

Published
2019

50. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience

Author

Conti, A., Peccerillo, F., Amerio, P., Balato, A., Bardazzi, F., Bianchi, L., Burlando, M., Cannavo, S. P., Chiricozzi, Andrea, Dapavo, P., De Simone, Clara, Fargnoli, Maria Concetta, Gambardella, A., Gisondi, P., Malagoli, P., Malara, G., Mugheddu, C., Offidani, A. M., Piaserico, S., Prignano, F., Stingeni, L., Pellacani, G., Chiricozzi A. (ORCID:0000-0002-6739-0387), De Simone C. (ORCID:0000-0002-0898-0045), Fargnoli M. C., Conti, A., Peccerillo, F., Amerio, P., Balato, A., Bardazzi, F., Bianchi, L., Burlando, M., Cannavo, S. P., Chiricozzi, Andrea, Dapavo, P., De Simone, Clara, Fargnoli, Maria Concetta, Gambardella, A., Gisondi, P., Malagoli, P., Malara, G., Mugheddu, C., Offidani, A. M., Piaserico, S., Prignano, F., Stingeni, L., Pellacani, G., Chiricozzi A. (ORCID:0000-0002-6739-0387), De Simone C. (ORCID:0000-0002-0898-0045), and Fargnoli M. C.

Abstract

N/a

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results